Aug 2026· Translational Oncology· Vol 72, pp. 102955· 0 citations· 36 references
Medicine
TL;DR
Unified DNA+RNA amplicon NGS delivered guideline-relevant biomarkers from 759 real-world NSCLC FFPE samples, including small biopsies and cytology, suggesting that a single low-input assay can often replace sequential DNA→RNA testing and reduce repeat biopsies.
Abstract
Highlights • Unified DNA+RNA amplicon NGS delivered guideline-relevant biomarkers from 759 real-world NSCLC FFPE samples, including small biopsies and cytology.• High success rates (>95%) across all specimen types suggest that a single low-input assay can often replace sequential DNA→RNA testing and reduce repeat biopsies.• Robust performance in 5–8-year archived FFPE samples (≥96% success) enables treatment decisions even when only old tissue blocks are available.• D+R NGS confirmed 99.3% of known fusions/exon-skipping events and rescued additional actionable alterations that would otherwise be missed by standard workflows.• Detecting 18.2% more targetable fusions in DNA-NGS–negative cases has the potential to change first-line treatment selection from empirical chemo/chemo-immunotherapy to matched TKIs.
Laboratory workflow optimization, particularly the adoption of hybrid-capture methodology, significantly improved NGS success rates in a nationwide nsNSCLC testing program, highlighting the need for targeted education and infrastructural investment to broaden equitable access to precision oncology in Brazil.
B. Araújo, R. Paes, A. Rodrigues et al.· Cancer Treatment and Researc...· 0 citations
Accurate detection and quantification of EGFR mutations are essential for molecular stratification in non‐small cell lung cancer (NSCLC). While next‐generation sequencing (NGS) enables comprehensive genomic profiling, droplet digital PCR (ddPCR) offers high sensitivity for predefined mutations. Large‐scale evaluati...
Ming Liu, Lin-Ping Lu, Qifang Lei et al.· iMetaMed· 0 citations
The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....
Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al.· Clinical Chemistry· 0 citations
Advances in cell-free DNA (cfDNA) processing and error-suppressed next-generation sequencing (NGS) have enabled detection of circulating tumor DNA (ctDNA) at low abundance for assessment of minimal residual disease (MRD). MRD testing requires high analytical specificity near the stochastic limit of rare-molecule sampli...
M. Clark, R. Prathapam, K. Bramlett et al.· Journal of Molecular Diagnos...· 0 citations
Background Next-generation sequencing (NGS) is essential for precision oncology, yet its clinical implementation is often hindered by limited sample quantity, complex workflows, and cross-contamination risks. We evaluated a modified One-Step Multiplex PCR (OS-MPCR) assay designed to streamline library construction whil...
Hai-Yan Feng, Xiao Hu, Lei Zhang et al.· PLoS ONE· 0 citations
LCx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information, and suggests that LBx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information.
M. Albitar, Ahmad Charifa, Sally Agersborg et al.· The journal of liquid biopsy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.